Molecular pathology of uveal melanoma

Eye (Basingstoke)

Volumn 27, Issue 2, 2013, Pages 230-242

  Coupland, S E ^a   Lake, S L ^a   Zeschnigk, M ^b   Damato, B E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cytogenetics; GEP; MLPA; Molecular alterations; Signalling pathways; Uveal melanoma

Indexed keywords

CYCLIN D1; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53;

CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; METASTASIS; METASTATIC MELANOMA; MOLECULAR PATHOLOGY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTRAL KARYOTYPING; UVEA MELANOMA;

EID: 84874086891     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.255     Document Type: Conference Paper

References (155)

1. Jay M, McCartney AC. Familial malignant melanoma of the uvea and p53: A Victorian detective story. Surv Ophthalmol 1993;37(6): 457-462
2. Easton D F, Steele L, Fields P, Ormiston W, Averill D, Daly PA et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61(1): 120-128
3. Houlston R S, Damato BE. Genetic predisposition to ocular melanoma. Eye (Lond) 1999;13(Part 1): 43-46
4. Abdel-Rahman M H, Pilarski R, Ezzat S, Sexton J, Davidorf FH. Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma. Fam Cancer 2010;9(3): 431-438
5. Damato B, Heimann H. Personalized treatment of uveal melanoma. Eye (Lond) 2012; e-pub ahead of print 23 November 2012; doi:10.1038/eye.2012.242
6. Einhorn L H, Burgess M A, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer 1974;34(4): 1001-1004
7. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O et al. Long-Term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93(8): 1042-1046
8. Mariani P, Servois V, Piperno-Neumann S. Therapeutic options in metastatic uveal melanoma. Dev Ophthalmol 2011;49: 166-181
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1): 57-70
10. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5): 646-674
11. An J, Wan H, Zhou X, Hu D N, Wang L, Hao L et al. A comparative transcriptomic analysis of uveal melanoma and normal uveal melanocyte. PLoS One 2011;6(1): E16516
12. Brantley Jr. M A, Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-Terminal region. Cancer Res 2000;60(16): 4320-4323
13. Brantley Jr. M A, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000;157(6): 1795-1801
14. Coupland S E, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 1998;82(8): 961-970
15. Coupland S E, Anastassiou G, Stang A, Schilling H, Anagnostopoulos I, Bornfeld N et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 2000;191(2): 120-126
16. van der Velden P A, Metzelaar-Blok J A, Bergman W, Monique H, Hurks H, Frants RR et al. Promoter hypermethylation: A common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 2001;61(13): 5303-5306
17. Babchia N, Calipel A, Mouriaux F, Faussat A M, Mascarelli F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf/ ERK. Invest Ophthalmol Vis Sci 2010;51(1): 421-429
18. Saraiva V S, Caissie A L, Segal L, Edelstein C, Burnier Jr. MN. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005;15(4): 245-250
19. Naus N C, ZuidervaartW, Rayman N, Slater R, van Drunen E, Ksander B et al. Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int J Cancer 2000;87(1): 151-153
20. Abdel-Rahman M H, Yang Y, Zhou X P, Craig E L, Davidorf F H, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol Jan 10 2006;24(2): 288-295
21. Ehlers J P, Worley L, Onken M D, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 2008;14(1): 115-122
22. Weber A, Hengge U R, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 2003;83(12): 1771-1776
23. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92(11): 2032-2038
24. Onken M D, Worley L A, Long M D, Duan S, Council M L, Bowcock AM et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49(12): 5230-5234
25. Van Raamsdonk C D, Bezrookove V, Green G et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457(7229): 599-602
26. Van Raamsdonk C D, Griewank K G, Crosby M B, Garrido M C, Vemula S, Wiesner T et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363(23): 2191-2199
27. Bauer J, Kilic E, Vaarwater J, Bastian B C, Garbe C, de Klein A. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 2009;101(5): 813-815
28. Calipel A, Abonnet V, Nicole O, Mascarelli F, Coupland S E, Damato B et al. Status of RASSF1A in uveal melanocytes and melanoma cells. Mol Cancer Res 2011;9(9): 1187-1198
29. Chana J S, Wilson G D, Cree I A, Alexander R A, Myatt N, Neale M et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999;83(1): 110-114
30. Sun Y, Tran B N, Worley L A, Delston R B, Harbour JW. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci 2005;46(5): 1561-1564
31. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager M J, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002;43(1): 1-8
32. Wu X, Zhou J, Rogers A M, Jänne P A, Benedettini E, Loda M et al. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 2012;22(2): 123-132
33. Heine B, Coupland S E, Kneiff S, Demel G, Bornfeld N, Hummel M et al. Telomerase expression in uveal melanoma. Br J Ophthalmol 2000;84(2): 217-223
34. Rohrbach J M, Riedinger C, Wild M, Partsch M. [Telomerase activity in uveal melanomas]. Ophthalmologe 2000;97(5): 359-363
35. Abdel-Rahman M H, Craig E L, Davidorf F H, Eng C. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin Cancer Res 2005;11(1): 73-78
36. Cools-Lartigue J, Marshall J C, Caissie A L, Saraiva V S, Burnier Jr., MN. Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions. Melanoma Res 2005;15(3): 141-145
37. Kirschmann D A, Seftor E A, Hardy K M, Seftor R E, Hendrix MJ. Molecular pathways: Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications. Clin Cancer Res 2012;18(10): 2726-2732
38. Bakalian S, Marshall J C, Logan P, Faingold D, Maloney S, Di Cesare S et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14(4): 951-956
39. Onken M D, Ehlers J P, Worley L A, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006;66(9): 4602-4609
40. Harbour JW. The genetics of uveal melanoma: An emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012;25(2): 171-181
41. Victor N, Ivy A, Jiang B H, Agani FH. Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis 2006;23(1): 87-96
42. Zuidervaart W, Pavey S, van Nieuwpoort F A, Packer L, Out C, Maat W et al. Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res 2007;17(6): 380-386
43. Anastassiou G, Tschentscher F, Zeschnigk M, Bornfeld N. Cadherin expression in uveal melanoma. Exp Eye Res 2002;74(3): 423-425
44. Baker J K, Elshaw S R, Mathewman G E, Nichols C E, Murray A K, Parsons MA et al. Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: Differences between in vitro and in vivo expression. Melanoma Res 2001;11(3): 265-273
45. Canovas D, Rennie I G, Nichols C E, Sisley K. Local environmental influences on uveal melanoma: Vitreous humor promotes uveal melanoma invasion, whereas the aqueous can be inhibitory. Cancer 2008;112(8): 1787-1794
46. Nareyeck G, Zeschnigk M, von der Haar D, Schilling H, Bornfeld N, Anastassiou G. Differential expression of tissue inhibitor of matrix metalloproteinases 3 in uveal melanoma. Ophthalmic Res 2005;37(1): 23-28
47. van der Velden P A, Zuidervaart W, Hurks M H, Pavey S, Ksander B R, Krijgsman E et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer 2003;106(4): 472-479
48. Zeschnigk M, Tschentscher F, Lich C, Brandt B, Horsthemke B, Lohmann DR. Methylation analysis of several tumour suppressor genes shows a low frequency of methylation of CDKN2A and RARB in uveal melanomas. Comp Funct Genomics 2003;4(3): 329-336
49. Asnaghi L, Ebrahimi K B, Schreck K C, Bar E E, Coonfield M L, Bell WR et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res 2012;18(3): 654-665
50. Neumann L C, Weinhausel A, Thomas S, Horsthemke B, Lohmann D R, Zeschnigk M. EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer. 2011;11: 380
51. Yang W, Chen P W, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 2008;49(6): 2518-2525
52. Hurks H M, Metzelaar-Blok J A, Mulder A, Claas F H, Jager MJ. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer 2000;85(5): 697-702
53. de Waard-Siebinga I, Hilders C G, Hansen B E, van Delft J L, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol 1996;234(1): 34-42
54. Whelchel J C, Farah S E, McLean I W, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 1993;34(8): 2603-2606
55. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumorinfiltrating macrophages (CD68( cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42(7): 1414-1421
56. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci 2004;45(1): 1-6
57. Jager M J, Ly L V, El Filali M, Madigan MC. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retin Eye Res 2010;30(2): 129-146
58. Herwig M C, Grossniklaus HE. Role of macrophages in uveal melanoma. Expert Rev Ophthalmol 2011;6(4): 405-407
59. Bronkhorst I H, Jager MJ. Uveal melanoma: The inflammatory microenvironment. J Innate Immun 2012;4(5-6): 454-462
60. Yu H, Fang D, Kumar S M, Li L, Nguyen T K, Acs G et al. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol 2006;168(6): 1879-1888
61. Kalirai H, Damato B E, Coupland SE. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Invest Ophthalmol Vis Sci 2011;52(11): 8458-8466
62. Singh A D, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology 2005;112(10): 1784-1789
63. Mooy C M, Van der Helm M J, Van der Kwast T H, De Jong P T, Ruiter D J, Zwarthoff EC. No N-ras mutations in human uveal melanoma: The role of ultraviolet light revisited. Br J Cancer 1991;64(2): 411-413
64. Soparker C N, O'Brien J M, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci 1993;34(7): 2203-2209
65. Cruz III, F, Rubin B P, Wilson D, Town A, Schroeder A, Haley A et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003;63(18): 5761-5766
66. Kilic E, Bruggenwirth H T, Verbiest M M, Zwarthoff E C, Mooy N M, Luyten GP et al. The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 2004;14(3): 203-205
67. Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F et al. Detection of BRAF gene mutation in primary choroidal melanoma tissue. Cancer Biol Ther 2006;5(2): 225-227
68. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs S L, Pe'er J et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003;44(7): 2876-2878
69. Ehlers J P, Harbour JW. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 2005;11(5): 1849-1853
70. Parrella P, Caballero O L, Sidransky D, Merbs SL. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci 2001;42(8): 1679-1684
71. Ehlers J P, Worley L, Onken M D, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res 2005;11(10): 3609-3613
72. Onken M D, Worley L A, Harbour JW. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res 2008;14(12): 3737-3745
73. Merbs S L, Sidransky D. Analysis of p16 (CDKN2/MTS-1/ INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci 1999;40(3): 779-783
74. Moulin A P, Clement G, Bosman F T, Zografos L, Benhattar J. Methylation of CpG island promoters in uveal melanoma. Br J Ophthalmol 2008;92(2): 281-285
75. Maat W, Beiboer S H, Jager M J, Luyten G P, Gruis N A, van der Velden PA. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49(4): 1291-1298
76. Worley L A, Long M D, Onken M D, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 2008;18(3): 184-190
77. Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis 2009;15: 2146-2154
78. Hoglund M, Gisselsson D, Hansen G B, White V A, Säll T, Mitelman F et al. Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004;108(1): 57-65
79. Damato B, Dopierala J A, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligationdependent probe amplification. Clin Cancer Res 2010;16(24): 6083-6092
80. Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: Implications for a bifurcated tumor progression pathway. Cancer Res 1999;59(13): 3032-3037
81. Tschentscher F, Husing J, Holter T, Kruse E, Dresen I G, Jöckel KH et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003;63(10): 2578-2584
82. Mensink H W, Vaarwater J, Kilic E, Naus N C, Mooy N, Luyten G et al. Chromosome 3 intratumor heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci 2009;50(2): 500-504
83. Maat W, Jordanova E S, van Zelderen-Bhola S L, Barthen E R, Wessels H W, Schalij-Delfos NE et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: Implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med 2007;131(1): 91-96
84. Dopierala J, Damato B E, Lake S L, Taktak A F, Coupland SE. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci 2010;51(10): 4898-4905
85. Bronkhorst I H, Maat W, Jordanova E S, Kroes W G, Schalij-Delfos N E, Luyten GP et al. Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med 2011;135(8): 1042-1047
86. Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P et al. Monosomy 3 by FISH in uveal melanoma: Variability in techniques and results. Surv Ophthalmol 2012;57(5): 463-473
87. White V A, McNeil B K, Thiberville L, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 during clonal evolution of a uveal melanoma: Association with morphologic heterogeneity. Genes Chromosomes Cancer 1996;15(2): 138-143
88. Callejo S A, Dopierala J, Coupland S E, Damato B. Sudden growth of a choroidal melanoma and multiplex ligationdependent probe amplification findings suggesting late transformation to monosomy 3 type. Arch Ophthalmol 2011;129(7): 958-960
89. Swanton C. Intratumor heterogeneity: Evolution through space and time. Cancer Res 2012;72(19): 4875-4882
90. Scholes A G, Liloglou T, Maloney P, Hagan S, Nunn J, Hiscott P et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci 2001;42(11): 2472-2477
91. Denhardt DT. Signal-Transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. Biochem J 1996;318(PT3): 729-747
92. Pache M, Glatz K, Bosch D, Dirnhofer S, Mirlacher M, Simon R et al. Sequence analysis and high-Throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003;443(6): 741-744
93. Rimoldi D, Salvi S, Lienard D, Lejeune F J, Speiser D, Zografos L et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003;63(18): 5712-5715
94. Griffin C A, Long P P, Schachat AP. Trisomy 6p in an ocular melanoma. Cancer Genet Cytogenet 1988;32(1): 129-132
95. Horsman D E, Sroka H, Rootman J, White VA. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogenet 1990;45(2): 249-253
96. Horsman D E, White VA. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer 1993;71(3): 811-819
97. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82(22): 1765-1769
98. Prescher G, Bornfeld N, Horsthemke B, Becher R. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 1992;339(8794): 691-692
99. Prescher G, Bornfeld N, Becher R. Two subclones in a case of uveal melanoma. Relevance of monosomy 3 and multiplication of chromosome 8q. Cancer Genet Cytogenet 1994;77(2): 144-146
100. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet 1995;80(1): 40-46
101. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel K H, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347(9010): 1222-1225
102. Sisley K, Rennie I G, Cottam D W, Potter A M, Potter C W, Rees RC. Cytogenetic findings in six posterior uveal melanomas: Involvement of chromosomes 3, 6, and 8. Genes Chromosomes Cancer 1990;2(3): 205-209
103. Wiltshire R N, Elner V M, Dennis T, Vine A K, Trent JM. Cytogenetic analysis of posterior uveal melanoma. Cancer Genet Cytogenet 1993;66(1): 47-53
104. Sisley K, Rennie I G, Parsons M A, Jacques R, Hammond D W, Bell SM et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19(1): 22-28
105. McNamara M, Felix C, Davison E V, Fenton M, Kennedy SM. Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization. Cancer Genet Cytogenet 1997;98(1): 4-8
106. Patel K A, Edmondson N D, Talbot F, Parsons M A, Rennie I G, Sisley K. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol 2001;85(12): 1440-1444
107. Sisley K, Tattersall N, DysonM, Smith K, Mudhar H S, Rennie IG. Multiplex fluorescence in situ hybridization identifies novel rearrangements of chromosomes 6, 15, and 18 in primary uveal melanoma. Exp Eye Res 2006;83(3): 554-559
108. Damato B, Duke C, Coupland S E, Hiscott P, Smith P A, Campbell I et al. Cytogenetics of uveal melanoma: A 7-year clinical experience. Ophthalmology 2007;114(10): 1925-1931
109. Singh A D, Aronow M E, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR et al. Chromosome 3 status in uveal melanoma: A comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci 2012;53(7): 3331-3339
110. Gordon K B, Thompson C T, Char D H, O'Brien J M, Kroll S, Ghazvini S et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res 1994;54(17): 4764-4768
111. Speicher M R, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld N et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994;54(14): 3817-3823
112. Ghazvini S, Char D H, Kroll S, Waldman F M, Pinkel D. Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genet Cytogenet 1996;90(2): 95-101
113. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42(2): 313-317
114. Hughes S, Damato B E, Giddings I, Hiscott P S, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer 2005;93(10): 1191-1196
115. Kilic E, van Gils W, Lodder E, Beverloo H B, van Til M E, Mooy CM et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci 2006;47(9): 3703-3707
116. Petrausch U, Martus P, Tonnies H, Bechrakis N E, Lenze D, Wansel S et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22(8): 997-1007
117. Naus N C, van Drunen E, de Klein A, Luyten G P, Paridaens D A, Alers JC et al. Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. Genes Chromosomes Cancer 2001;30(3): 267-273
118. White J S, Becker R L, McLean I W, Director-Myska A E, Nath J. Molecular cytogenetic evaluation of 10 uveal melanoma cell lines. Cancer Genet Cytogenet 2006;168(1): 11-21
119. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 2000;122(1): 13-17
120. Scholes A G, Damato B E, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003;44(3): 1008-1011
121. Hausler T, Stang A, Anastassiou G, Jöckel K H, Mrzyk S, Horsthemke B et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 2005;116(6): 909-913
122. Shields C L, Ganguly A, Materin M A, Teixeira L, Mashayekhi A, Swanson LA et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: The Deborah Iverson, M D, Lectureship. Arch Ophthalmol 2007;125(8): 1017-1024
123. Shields C L, Ganguly A, Bianciotto C G, Turaka K, Tavallali A, Shields JA. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2010;118(2): 396-401
124. Thomas S, Putter C, Weber S, Bornfeld N, Lohmann D R, Zeschnigk M. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: A long-Term follow-up study. Br J Cancer 2012;106(6): 1171-1176
125. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: Correlation with metastatic death. Invest Ophthalmol Vis Sci 2009;50(7): 3048-3055
126. Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond) 2012;26(9): 1157-1172
127. Vaarwater J, van den Bosch T, Mensink H W, van Kempen C, Verdijk R M, Naus NC et al. Multiplex ligationdependent probe amplification equals fluorescence in-situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma. Melanoma Res 2011;22(1): 30-37
128. Onken M D, Worley L A, Person E, Char D H, Bowcock A M, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007;13(10): 2923-2927
129. Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, Delattre O et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 2009;50(6): 2572-2580
130. Lake S L, Coupland S E, Taktak A F, Damato BE. Wholegenome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci 2010;51(10): 4884-4891
131. McCannel T A, Burgess B L, Nelson S F, Eskin A, Straatsma BR. Genomic identification of significant targets in ciliochoroidal melanoma. Invest Ophthalmol Vis Sci 2010;52(6): 3018-3022
132. Abi-Ayad N, Kodjikian L, Couturier J. [Genomic techniques used in uveal melanoma: A literature review]. J Fr Ophtalmol 2011;34(4): 259-264
133. White V A, Chambers J D, Courtright P D, Chang W Y, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83(2): 354-359
134. Damato B, Eleuteri A, Taktak A F, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011;30(5): 285-295
135. Coupland S E, Kalirai H, Baudo M, Maye U, Zeschnigk M, Damato B. Quality assessment of multiplex ligationdependent probe amplification (MLPA) in uveal melanoma by comparison with array comparative genomic hybridization (aCGH) and microsatellite analysis (MSA). IOVS 2012
136. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol 2009; 148(6): 823-829 e821
137. Onken M D, Worley L A, Tuscan M D, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12(4): 461-468
138. Onken M D, Worley L A, Char D H, Augsburger J J, Correa Z M, Nudleman E et al. Collaborative Ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8): 1596-1603
139. Harbour J W, Onken M D, Roberson E D, Duan S, Cao L, Worley LA et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330(6009): 1410-1413
140. Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 2010;71(3): 666-674
141. Jensen D E, Proctor M, Marquis S T, Gardner H P, Ha S I, Chodosh LA et al. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16(9): 1097-1112
142. Abdel-Rahman M H, Pilarski R, Cebulla C M, Massengill J B, Christopher B N, Boru G et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48(12): 856-859
143. Wiesner T, Obenauf A C, Murali R, Fried I, Griewank K G, Ulz P et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43(10): 1018-1021
144. Testa J R, Cheung M, Pei J, Below J E, Tan Y, Sementino E et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43(10): 1022-1025
145. Njauw C N, Kim I, Piris A, Gabree M, Taylor M, Lane AM et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012;7(4): E35295
146. Carbone M, Korb Ferris L, Baumann F, Napolitano A, Lum C A, Flores EG et al. BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10(1): 179
147. Lake S L, Damato B E, Taktak AFG, Lloyd B H, Coupland SE. Copy number alteration of genes key to metastatic progression in uveal melanoma. Am J Pathol, in press
148. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133(3421): 571-573
149. Fuchs E. Das Sarkom des Uvealtractus. Graefe's Archiv für Ophthalmologie 1882; XII(2): 233
150. Scala S, Ierano C, Ottaiano A, Franco R, La Mura A, Liguori G et al. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother 2007;56(10): 1589-1595
151. Anastassiou G, Coupland S E, Stang A, Boeloeni R, Schilling H, Bornfeld N. Expression of Fas and Fas ligand in uveal melanoma: Biological implication and prognostic value. J Pathol 2001;194(4): 466-472
152. Patel M, Smyth E, Chapman P B, Wolchok J D, Schwartz G K, Abramson DH et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011;17(8): 2087-2100
153. Woodman SE. Metastatic uveal melanoma: Biology and emerging treatments. Cancer J 2012;18(2): 148-152
154. Landreville S, Agapova O A, Matatall K A, Kneass Z T, Onken M D, Lee RS et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2011;18(2): 408-416
155. Cook S A, Damato B, Marshall E, Salmon P. Psychological aspects of cytogenetic testing of uveal melanoma: Preliminary findings and directions for future research. Eye (Lond) 2009;23(3): 581-585